HEALTHSTORY 590· JUNE 21, 2026

GLP-1 Weight Loss Drug Race Heats Up as Pfizer and Amgen Challenge Novo Nordisk and Eli Lilly

The scramble to compete in the GLP-1 weight loss drug market is intensifying. Pharmaceutical companies Pfizer and Amgen are developing products to take on Novo Nordisk's Wegovy and Eli Lilly's Zepbound

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 589Fentanyl-Linked Chinese Network Ran Fake 'Zksync.jp' Token Scam, Nikkei Reports, With Losses Topping $1 Million NEXT STORY 591 →Pomerantz Files Class Action Against ServBanc Holdco, IF Bancorp Board Over IROQ Stock

Keep reading

More from the desk.

08HEALTH

Senate health panel clears Trump's CDC and pandemic preparedness nominees

A Senate committee vote, meaning a panel decision that sends nominees to the full chamber for final confirmation, moved two of President Trump's public health choices forward on Thursday. Erica Schwartz, nominated to lead the Centers for…

health1 MIN

31HEALTH

More than 200 ADA members demand leadership resign after scientists expelled in New Orleans

Five researchers were removed from a major diabetes organization's annual scientific conference, a once-a-year gathering where clinicians present new findings and debate the direction of clinical practice, in New Orleans last month. More…

health2 MIN

51HEALTH

Drug spending is up. PhRMA wants journalists to frame it differently.

Prescription drug spending is rising, and the pharmaceutical industry's main lobbying organization is running a campaign to change how reporters describe it. Lobbying, at its most basic, means paid outreach

health2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk